{"organizations": [], "uuid": "69c2a271a5f303da01c509dc330b30bb9b84e736", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-merck-announces-q1-gaap-eps-of-027/brief-merck-announces-q1-gaap-eps-of-0-27-idUSASC09YI6", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck Announces Q1 GAAP EPS Of $0.27", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T14:15:00.000+03:00", "replies_count": 0, "uuid": "69c2a271a5f303da01c509dc330b30bb9b84e736"}, "author": "", "url": "https://www.reuters.com/article/brief-merck-announces-q1-gaap-eps-of-027/brief-merck-announces-q1-gaap-eps-of-0-27-idUSASC09YI6", "ord_in_thread": 0, "title": "BRIEF-Merck Announces Q1 GAAP EPS Of $0.27", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters st", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "none"}, {"name": "eisai", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 11:16 AM / Updated 6 minutes ago BRIEF-Merck Announces Q1 GAAP EPS Of $0.27 Reuters Staff\nMay 1 (Reuters) - Merck & Co Inc:\n* MERCK ANNOUNCES FIRST-QUARTER 2018 FINANCIAL RESULTS * Q1 GAAP EARNINGS PER SHARE $0.27\n* Q1 EARNINGS PER SHARE VIEW $1.00 — THOMSON REUTERS I/B/E/S\n* Q1 NON-GAAP EARNINGS PER SHARE $1.05\n* NARROWS AND RAISES 2018 FULL-YEAR REVENUE RANGE TO BE BETWEEN $41.8 BILLION AND $43.0 BILLION\n* FIRST-QUARTER 2018 GAAP EPS WAS $0.27, REFLECTING A $1.4 BILLION AGGREGATE CHARGE RELATED TO FORMATION OF A COLLABORATION WITH EISAI * LOWERS 2018 GAAP EPS RANGE TO BE BETWEEN $2.45 AND $2.57\n* NARROWS AND RAISES 2018 FULL-YEAR NON-GAAP EPS RANGE TO BE BETWEEN $4.16 AND $4.28\n* QTRLY JANUVIA/JANUMET SALES $1,424 MILLION VERSUS $1,335 MILLION REPORTED LAST YEAR\n* FIRST-QUARTER PHARMACEUTICAL SALES INCREASED 9 PERCENT TO $8.9 BILLION, INCLUDING A 5 PERCENT POSITIVE IMPACT FROM FOREIGN EXCHANGE\n* QTRLY KEYTRUDA SALES $1,464 MILLION VERSUS $584 MILLION REPORTED LAST YEAR\n* FIRST-QUARTER 2018 WORLDWIDE SALES WERE $10.0 BILLION, AN INCREASE OF 6 PERCENT\n* QTRLY REMICADE SALES $167 MILLION VERSUS $229 MILLION REPORTED LAST YEAR * Q1 REVENUE VIEW $10.11 BILLION — THOMSON REUTERS I/B/E/S\n* FY2018 EARNINGS PER SHARE VIEW $4.20, REVENUE VIEW $41.89 BILLION — THOMSON REUTERS I/B/E/S\n* QTRLY PHARMACEUTICAL SALES INCREASE WAS PRIMARILY DRIVEN BY GROWTH IN ONCOLOGY, HOSPITAL ACUTE CARE AND DIABETES\n* MERCK - PHARMACEUTICAL SALES GROWTH IN QUARTER WAS PARTIALLY OFFSET BY LOWER SALES IN VIROLOGY, LARGELY REFLECTING A SIGNIFICANT DECLINE IN ZEPATIER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-05-01T14:15:00.000+03:00", "crawled": "2018-05-01T14:28:52.004+03:00", "highlightTitle": ""}